Financial Results for the First Half of 2025 – Steady Growth Momentum
Financial Results for the First Half of 2025 – Steady Growth Momentum
Peania, September 18, 2025 – Lavipharm Group reports an increase in its consolidated sales during the First Half of 2025. Specifically, consolidated sales from continuing operations amounted to €31.0 million, compared to €29.3 million in the corresponding period of 2024, recording an increase of 5.7%. Consolidated Sales, after deduction of rebates and clawback, amounted to €26.7 million, compared to €25.0 million in the corresponding period of 2024, reflecting an increase of 6.8%. Adjusted EBITDA stood at €7.7 million, versus €5.9 million in the First Half of 2024, marking a 29.4% increase. Consolidated EBITDA for the period includes the profit from the sale of subsidiary Pharma Plus. This profit, amounting to €973 thousand, is presented in the Group’s financial statements as a result of discontinued operations. The accounting impact of the valuation of the stock option and stock award plans amounted to €480 thousand, compared to €675 thousand in the corresponding period of 2024. It should be noted that the obligations arising from the implementation of these programs affect EBITDA, according to IFRS, but do not require any cash outflow.
Financial Results for the First Half of 2025 – Steady Growth Momentum